EM1902E "Cardiac Amyloidosis: The Zebra is Losing its Stripes" (IM GR-020119)
PURPOSE AND OVERVIEW:
To discuss the current management strategies for cardiac amyloidosis, including the pathophysiology and prognosis of cardiac amyloidosis, the state-of-the-art diagnostic strategies for cardiac amyloidosis, and the current and new treatments on the horizon for cardiac amyloidosis.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand the pathophysiologic, prognostic, and clinical differences between light-chain cardiac amyloidosis (AL) and transthyretin cardiac amyloidosis (ATTR)
- Understand the clinical clues that might be consistent with a diagnosis of cardiac amyloidosis
- Identify the appropriate diagnostic strategies to secure the diagnosis of cardiac amyloidosis and differentiate AL from ATTRm/wt with a focus on 99m technetium pyrophosphate scans and serum free light chain assays plus serum immunofixation.
- Understand the medical management of heart failure in patients with cardiac amyloidosis and how this differs from more typical heart failure populations
- Recognize US FDA approved ATTR pharmacotherapy and newer therapies on the horizon and be able to differentiate categories of ATTR therapies including TTR silencers, TTR stabilizers, and amyloid fibril disruptors.
Justin L. Grodin, M.D., MPH, FACC, FHFSA
Assistant Professor of Internal Medicine
Division of Cardiology
Dr. Grodin was born and raised in El Paso, Texas. He completed a Bachelor of Science in Chemistry at the University of Texas (UT) at Austin and then transitioned to medical school (2005-2009) at the UT Southwestern Medical Center where he also completed his residency training in internal medicine (2009-2012). Following this, he completed fellowships in Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology at the Cleveland Clinic (2012-2016) and attended the Harvard T.H. Chan School of Public Health where he received the degree of Master of Public Health. He has since returned to UT Southwestern in the Fall of 2016 joining the Division of Cardiology. His clinical focus is in advanced heart failure, cardiac amyloidosis, hypertrophic cardiomyopathy, cardiac transplantation, left-ventricular assist devices, and cardiac critical care. In addition, he splits his time as a clinical epidemiologist focusing on heart failure outcomes research.
- 1.00 AMA